The Association between Serum Leptin and Post Stroke Depression: Results from a Cohort Study

Yan-tao Li1,*, Ye Zhao2,*, Hua-jing Zhang3, Wen-li Zhao4

1 Department of Prevention and Health Care, Tianjin Nankai Hospital, Tianjin, P. R. China, 2 Department of Clinical Research, Tianjin Nankai Hospital, Tianjin, P. R. China, 3 Department of Pediatrics, Tianjin Wuqing Hospital of Traditional Chinese Medicine, Tianjin, P. R. China, 4 Department of Neurology, Tianjin Nankai Hospital, Tianjin, P. R. China

Abstract

Background: Depression is a frequent mood disorder that affects around a third of stroke patients and has been associated with poorer outcomes. Our aim was to determine whether there was a relationship between inflammatory markers (leptin) and post-stroke depression (PSD).

Methods: One hundred and ninety-one ischemic stroke patients admitted to the hospital within the first 24 hours after stroke onset were consecutively recruited and followed up for 3 months. Enzyme-linked immunosorbent assay (ELISA) was used to measure serum levels of leptin at admission. Based on the symptoms, diagnoses of depression were made in accordance with DSM-IV criteria for post-stroke depression at 3 month.

Results: Forty-four patients (23.0%) were diagnosed as having major depression at 3 month. Patients with depression showed higher serum leptin levels at 3 month after stroke (32.2 [IQR, 20.8–57.7] v. 9.9 [IQR, 4.6–13.1]ng/ml, respectively; \(P = 0.000\)). Serum levels of leptin \(\geq 20\) ng/ml were independently associated with PSD [odds ratio (OR) 20.23, 95% confidence interval (CI) 9.11–51.26, \(P = 0.000\)], after adjusting for possible confounders.

Conclusions: Serum leptin levels elevated at admission were found to be associated with PSD and may provide a new proposal for the treatment of PSD.

Introduction

Depression is particularly prevalent among stroke survivors, affecting approximately a third of individuals [1]. China has 2.5 million new stroke cases each year and 7.5 million stroke survivors [2]. Thus, there will be 3.0 million stroke patients with depression. Patients with depression experience worse stroke-related outcomes in the form of greater functional disability and higher mortality [3], and, finally with worse rehabilitation outcomes [4]. Moreover, an improvement of depressive symptoms has been associated with a better functional recovery [4]. Early recognition of depression symptoms and introduction of pharmacological treatment is of great importance in the reduction of stroke complications and stroke mortality as well as for better functional outcomes [5], making the prevention and management of post-stroke depression (PSD) an important area of research.

Chronic inflammation has been suggested as an important mechanism related to depression [6–7], such as C-reactive protein (CRP), interleukin-6 (IL-6), IL-1 [8], IL-18[9]. Likewise, Kim et al [10] reported that reduced anti-inflammatory cytokine function was associated with PSD, supporting the cytokine hypothesis in its etiology.

Leptin is a hormone secreted by adipose tissue in direct proportion to amount of body fat. It circulates as a 16-kDa protein and is transported across the blood–brain barrier by a saturable system to exert its central effects [11]. Its main function are focused on behavior and energy balance control [12]. In addition, it has been studied on account of its participation in anti-obesity [13], neuroprotection[14], reducing oxidative stress[15], protective and harmful effects on the cardiovascular (CV) system[16] and as a vascular risk factor for stroke[17].

Lu et al [10] reported that leptin has been associated with the development of depression in clinical and experimental studies. Whereas, some authors have found higher leptin levels in patients with depression [19–20], others have reported lower leptin levels [21–22]. Thus, the role of leptin in patients with depression remains inconsistent. Interestingly, there was rare study on serum leptin levels in patients with PSD. Therefore, our aim was to determine whether there was a relationship between leptin and PSD in Chinese population.
Methods

Study population

Two hundred and fifty-six patients with a first episode of acute ischemic stroke admitted to our hospital within the first 24 h of stroke onset were prospectively included in the study. Patients were included if they were admitted to the emergency department with an acute ischemic stroke defined according to the World Health Organization criteria [23]. Patients with subarachnoid or intracranial hemorrhage, decreased level of consciousness, severe aphasia or dysarthria, or psychiatric illness, severe infectious or inflammatory diseases, and life expectancy <3 months were excluded.

One hundred and forty-five out of 256 patients (56.6%) were male, with a mean age of 68.6 ± 10.1 years. Sixty-five patients were not evaluated at 3 months (thirty-one patients died and 9 refused to attend the follow-up, nine patients had difficulty in being transported to hospital, and 16 patients were lost to follow-up); the remaining 191 patients were valid for analysis. Written informed consent was obtained after having provided verbal and written information to participants or nearest relatives when relevant. Ethics approval was granted by The Ethics Committee for Medical Research at Tianjin Nankai Hospital.

Clinical variables

At baseline, age, sex, body mass index and history of risk factors were obtained. Stroke subtype was classified according to TOAST (Trial of ORG 10172 in Acute Stroke Treatment) criteria [24]. Routine blood and biochemical tests, brain CT/MRI scan were performed in all patients at admission. MRI with diffusion-weighted imaging (DWI) was available in some patients. The infarct volume was calculated by using the formula 0.5 · a · b · c (where a is the maximal longitudinal diameter, b is the maximal transverse diameter perpendicular to a and c is the number of 10-mm slices containing infarct) [25].

Stroke severity was evaluated by trained neurologists using the NIHSS at admission [26]. Functional outcomes were evaluated by the modified Rankin Scale (mRS) at 3 month [27]. A favorable functional outcome was defined as a mRS score of 0 to 2 points, while an unfavorable functional outcome was defined as a mRS score of 3 to 6 points.

| Table 1. Basal characteristic of patients with acute ischemic stroke |
|---------------------------------------------------------------|
| **Baseline Characteristics** | **Depression patients (n=44)** | **No depression (n=147)** | **P** |
| Age (years), mean(SD) | 71.2 (9.0) | 64.9 (12.1) | 0.009 |
| Female sex, % | 59.1 | 39.5 | 0.021 |
| BMI(kg m^2, IQR) | 26.8(23.1–29.4) | 23.9(21.8–27.2) | 0.001 |
| Hypertension, % | 47.7 | 49.7 | 0.822 |
| Diabetes at baseline, % | 40.9 | 37.4 | 0.693 |
| Hypercholesterolemia, % | 38.6 | 39.5 | 0.873 |
| Coronary heart disease, % | 29.5 | 27.2 | 0.717 |
| Family history of stroke, % | 22.7 | 20.4 | 0.401 |
| Admission median NIHSS score (IQR) | 7 (4–12) | 6(3–10) | 0.126 |
| mRS at 3 month, median (IQR) | 3(1–3) | 2(1–3) | 0.221 |
| Infarct volume (ml, mean(SD)) | 10.8(1.4) | 10.5(1.3) | 0.671 |
| Time from onset to inclusion (hr, IQR) | 4.8 (2.3–11.2) | 5.0(2.4–11.3) | 0.452 |
| Widowhood (%) | 40.9 | 18.4 | 0.002 |
| Living with offspring (%) | 36.4 | 13.6 | 0.001 |
| Days of hospitalization, median (IQR) | 10(7–13) | 9(5–12) | 0.526 |
| TOAST classification (%) | | | 0.231 |
| a. Large artery | 15.9 | 17.0 | – |
| b. Small artery | 18.2 | 18.4 | – |
| c. Cardioembolism | 36.4 | 37.4 | – |
| d. Other cause | 13.6 | 14.3 | – |
| e. Unknown | 15.9 | 12.9 | – |
| Laboratory findings | | | |
| White cell count, ×10^9/L (Median, IQR) | 7.7 (5.9–8.6) | 7.6 (5.5–8.4) | 0.826 |
| Glucose level, mmol/L (Median, IQR) | 5.44(4.75–6.51) | 5.38 (4.85–6.55) | 0.324 |
| Hs-CRP, mg/dL (Median, IQR) | 0.88 (0.36–2.44) | 0.40 (0.21–1.20) | 0.003 |
| HCY, umol/L (Median, IQR) | 18.8(13.9–23.7) | 14.6 (11.4–18.5) | 0.023 |
| Leptin (ng/ml) | 32.2(20.8–57.7) | 9.9(4.6–13.1) | <0.001 |

Notes: *Mann–Whitney U test, student’s t test or Chi-square test was used.

Results are expressed as percentages or as medians (IQR) and means (SD); hs-CRP: high-sensitivity C-reactive protein; HCY: homocysteine; BMI, Body Mass Index.

doi:10.1371/journal.pone.0103137.t001
Figure 1. Correlation between serum leptin levels and others predictors. (a) Correlation between the serum leptin levels and BMI; (b) Correlation between serum leptin levels and Hs-CRP; (c) Correlation between the serum leptin levels and the National Institutes of Health Stroke Scale (NIHSS) score.

doi:10.1371/journal.pone.0103137.g001

Table 2. Adjusted OR of depression for leptin levels at admission in the stroke patients

| Parameter                        | OR  | 95% CI       | P     |
|----------------------------------|-----|--------------|-------|
| Age(increase per unit)           | 1.05| 1.02–1.10    | 0.012 |
| Males                            | 0.84| 0.72–1.06    | 0.023 |
| Widowhood                        | 1.55| 1.21–2.06    | 0.009 |
| Living with offspring            | 1.63| 1.06–2.46    | 0.018 |
| NIHSS on admission(increase per unit) | 1.31| 0.89–2.26    | 0.236 |
| BMI(increase per unit)           | 1.18| 1.07–1.31    | 0.002 |
| Hs-CRP(increase per unit)        | 1.13| 0.79–2.25    | 0.341 |
| HCY(increase per unit)           | 1.16| 0.76–2.42    | 0.526 |
| Leptin levels at admission(increase per unit) | 1.15| 1.05–1.25    | <0.001|
| Leptin levels at admission(≥20 ng/ml) | 20.23| 9.11–51.26  | <0.001|

OR, odds ratio; CI, confidence interval; NIHSS, National Institutes of Health Stroke Scale; BMI, body mass index; Hs-CRP, High-sensitivity C-reactive protein; HCY, homocysteine.

doi:10.1371/journal.pone.0103137.t002
Depression assessments were conducted by a neurologist/psychiatrist who was unaware of the type, size and location of the index stroke at the time of 3 months after stroke onset. Previous history of psychiatric disease and depression, educational level and people living with the patient were recorded at admission. Clinical depression was diagnosed according to DSM-III-R criteria [28] using algorithms based on psychiatric interview and neuropsychiatric examination. The presence of anhedonia and depressive mood was essential for the diagnosis.

Figure 2. Serum leptin levels in acute ischemic stroke patients with depression and no depression. Mann–Whitney U-test. All data are medians and interquartile ranges (IQR). Significantly higher in stroke patients with depression as compared to no depression (P = 0.000).

doi:10.1371/journal.pone.0103137.g002

Figure 3. Receiver operator characteristic curve demonstrating sensitivity as a function of 1-specificity for predicting the depression within 3 month based on the combined model and the relative contribution of each marker alone (initial cohort). This combined model had an area under the receiver operator characteristic curve of 0.876 (95%CI, 0.815–0.938) [0.697 (95%CI, 0.609–0.789) for NIHSS score; 0.667 (95%CI, 0.571–0.763) for BMI; 0.650 (95%CI, 0.556–0.744) for Hs-CRP; 0.860 (95%CI, 0.799–0.924) for leptin].

doi:10.1371/journal.pone.0103137.g003
Laboratory tests

Fasting venous blood was collected from all participants in vacutainer tubes and quickly centrifuged to avoid glycolysis. Serum samples were kept at −80°C until assay. Biomarker concentrations were measured in a central laboratory by investigators blinded to the clinical outcomes and neuroimaging findings. The serum levels were measured using with a commercially available quantitative enzyme-linked immunosorbent assay (ELISA) kit (Abcam, China). The lower detection limit was 2 ng/ml and the line range was 2–400 ng/ml. The intra-assay coefficient of variation [CV] and inter-assay CV were 4.6–7.5% and 5.3%–8.8%, respectively.

Statistical analyses

The results are expressed as percentages for categorical variables and as mean (standard deviation, S.D.) or median (interquartile range, IQR) for the continuous variables depending on their normal distribution. Correlations among continuous variables were assessed by the spearman rank-correlation coefficient. Proportions were compared using the Chi-square test, and the student’s t test or the Mann–Whitney test was used to compare continuous variables between groups as appropriate. The influence of serum leptin levels on PSD was performed by binary logistic regression analysis, which allows adjustment for confounding factors (age, sex, body mass index/BMI, stroke syndrome, stroke etiology, the NIHSS score, infarct volume, vascular risk factors, others blood biomarkers and a history of depression). The results are expressed as adjusted odds ratios (ORs) with the corresponding 95% confidence intervals (CIs). Receiver operating characteristic (ROC) curves were utilized to evaluate the accuracy of serum leptin to predict PSD. Area under the curve (AUC) was calculated as measurements of the accuracy of the test. All statistical analysis was performed with SPSS for Windows, version 19.0 (SPSS Inc., Chicago, IL, USA). Statistical significance was defined as p<0.05.

Results

The study cohort consisted of 256 patients at baseline (stroke admission). By the time of follow-up at 3 month, leaving 191 individuals were included in our study. The mean age was 68.5 (SD: 10.4) years and 44.0% were women. The median serum leptin on admission was 12.9 [IQR, 6.6—20.8] ng/ml. The median NIHSS score on admission was 6 points (IQR, 3 to 11). At 3 month, seventy-nine patients (41.4%) showed depression and in 44 individuals were included in our study. The mean age was 68.5 (SD: 10.4) years and 44.0% were women. The median serum leptin to predict PSD. Area under the curve (AUC) was calculated as measurements of the accuracy of the test. All statistical analysis was performed with SPSS for Windows, version 19.0 (SPSS Inc., Chicago, IL, USA). Statistical significance was defined as p<0.05.

Discussion

We found that patients with high leptin levels have a higher risk of developing major depression 3 months after stroke, even after adjustments for others risk factors. This correlation was more pronounced among men when compared with women. Consistent with our results, a recently published study including 104 patients with stroke showed that leptin was a powerful biological marker of risk of developing depression 1 month after stroke [29]. Similarly, Pasco et al [30] found that elevated serum leptin predicted subsequent development of a depressive disorder after adjusted BMI, medications or other lifestyle factors in female non-smokers.

Previous study found that the prevalence of PSD varies over time with an apparent peak 3–6 months after stroke and subsequent decline reaching about 50% of the initial rates at one year [6]. In our study, the prevalence of 3 months after stroke was 23.0%. Consistent with this, Jimez et al [29] reported that 22.1% of stroke patients were diagnosed as having major depression at 1 month after stroke.

In this study, we found that elevated serum leptin level was associated with PSD. In humans, hyperleptinemia has been associated with increased intima thickness and also seems to increase vascular calcification [31]. In addition, high leptin associates with left ventricular hypertrophy [32] in hypertensive
subjects, independently of actual BP levels. Hyperleptinemia also associates with fibrinolytic abnormalities [33].

Interestingly, previous studies in humans have had different results, and both increased [34–35] and decreased [36–37]. Leptin levels in depressed patients were found, while no association was reported by Deuschle et al [38]. Furthermore, Milaneschi et al [39] reported that low leptin signaling rather than low leptin concentration is a risk factor for depression and the relationship between leptin blood concentrations and depressive symptoms was modified by abdominal adiposity.

Leptin may influence depressive symptoms via different biological mechanisms. Firstly, leptin induces neurogenesis and angiogenesis after stroke and leads to increased leptin receptor and pAMPK concentrations. Leptin receptors are expressed in the hippocampus and amygdala, suggesting a potential neuroactive function [40]. Leptin receptors are also present on endothelial cells may play role in atherogenesis and impairment of vascular function [17]. In vascular smooth muscle cells, leptin stimulates vascular smooth muscle proliferation and migration [41]. Secondly, leptin has also been shown to affect hippocampal and cortical structure through its actions on neurogenesis, axon growth, synaptogenesis and dendritic morphology regulation [42]. Thirdly, elevated serum leptin in depression might in turn further promote corticotropin-releasing hormone (CRH) release, as shown in animals and, hence, contribute to HPA system hyperactivity seen in depression [43]. Fourthly, interestingly, it has been shown that leptin may partially mediate the pathway from expanded adipose tissue to pro-inflammatory biomarkers increase [39]. In animal models it has been shown that C-reactive protein, the acute phase protein produced by hepatocytes in response to pro-inflammatory cytokines stimulation, may directly bind to leptin and attenuate its physiological functions [44]. Furthermore, Penninx et al [45] indicated that depression was associated with obesity-related metabolic alterations, and leptin has been proposed to play a role in this process [46]. In this study, we also found a significantly positive correlation between serum levels of leptin and BMI (P = 0.001). In addition, obesity caused by leptin may be associated with other lifestyle factors considered bio-behavioral risk factors for depression, and obesity may increase psychological distress and depressive symptoms [39].

This study has a number of limitations. The major limitation of our study was that we were not able to examine the risk factors for depressive episodes such as, lack of social support, poverty, family violence, and increased life stress. Secondly, insulin was not measured in this study, while Soderberg et al [47] found a close association between circulating leptin and insulin levels. Thirdly, the serum level of leptin was tested only one time at admission, further studies are needed to assess how leptin levels change across time after stroke and whether levels drawn at later points provide improved prognostic information. Lastly, the study subjects were few (n = 191) and came from only one clinic. Therefore, our findings may not be generalizable to other Chinese stroke patients. Further research is needed.

In conclusion, in spite of these limitations, our findings of this study remain important and demonstrate a strong relationship between leptin serum levels at admission and the development of PSD within the 3 months in Chinese population. Further studies are advocated to confirm this association, which may provide new proposal for the treatment of PSD.

**Author Contributions**

Conceived and designed the experiments: YTL YZ WLZ. Performed the experiments: YTL YZ HJZ. Analyzed the data: YTL WLZ. Contributed reagents/materials/analysis tools: YTL YZ WLZ. Contributed to the writing of the manuscript: WLZ.

**References**

1. Linden T, Blomstrand C, Skoog I (2007) Depressive disorders after 20 months in elderly stroke patients: a case-control study. Stroke 38: 1860–1863.
2. Tu WJ, Dong X, Zhao SJ, Yang DG, Chen H (2013) Prognostic value of plasma neuroendocrine biomarkers in patients with acute ischemic stroke. Journal of Neuroendocrinology 25: 721–778.
3. Ellis C, Zhao Y, Egge LE (2010) Depression and increased risk of death in adults with stroke. Journal of psychosomatic research 68: 545–551.
4. Saxena SK, Ng TP, Koh G, Yong D, Fong NP (2007) Is improvement in energy balance. The Journal of clinical investigation 121: 2087–2093.
5. Vong L, Ye C, Yang Z, Choi B, Chua S Jr, et al. (2011) Leptin action on growth, synaptogensis and dendritic morphology regulation [42].
6. Dauter R, O'Connor JC, Lawson MA, Kelley KW (2011) Inflammation-associated depression: from serotonin to kynurenine. Psychoneuroendocrinology 36: 426–436.
7. Raison CL, Miller AH (2013) Role of Inflammation in Depression: Implications for Phenomenology, Pathophysiology and Treatment. Inflammation in Psychiatry 28: 33–48.
8. Howren MB, Lamkin DM, Suls J (2009) Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosomatic medicine 71: 171–186.
9. Yang L, Zhang Z, Sun D, Xu Z, Zhang X, et al. (2010) The serum interleukin-18 is a potential marker for development of post-stroke depression. Neurrol Res 32: 340–346.
10. Kim JM, Stewart R, Kim SW, Shin IS, Kim JT, et al. (2012) Associations of cytokine gene polymorphisms with post-stroke depression. World J Biol Psychiatry 13: 579–87.
11. Banks WA (2004) The many lives of leptin. Peptides 25: 331–338.
12. Saxena SK, Ng TP, Koh G, Yong D, Fong NP (2007) Is improvement in energy balance. The Journal of clinical investigation 121: 2087–2093.
13. Vong L, Ye C, Yang Z, Choi B, Chua S Jr, et al. (2011) Leptin action on growth, synaptogensis and dendritic morphology regulation [42].
14. Dauter R, O'Connor JC, Lawson MA, Kelley KW (2011) Inflammation-associated depression: from serotonin to kynurenine. Psychoneuroendocrinology 36: 426–436.
15. Zhang Jr JY, Si YL, Liao J, Yan GT, Deng ZH, et al. (2012) Leptin administration alleviates ischemic brain injury in mice by reducing oxidative stress and subsequent neuronal apoptosis. J Trauma Acute Care Surg 72: 982–991.
16. Kraus T, Haack M, Schuld A, Hinze-Selch D, Pollmacher T (2001) Low leptin levels but norma body mass indices in patients with depression or schizophrenia. Psychosom Med 74: 483–488.
17. Labad J, Price JF, Strachan MWJ, Foskes FG, Deary JJ, et al. (2012) Leptin levels and depressive symptoms in people with type 2 diabetes: the edinburgh type 2 diabetes study. Psychosom Med 74: 39–43.
18. La XY, Kim CS, Frazer A, Zhang W (2006) Leptin: a potential novel antidepressant. Proc Natl Acad Sci U S A 103: 1593–1598.
19. Harris JA, Ahmed Y, Stoyanova N, Hooper WC, De Stærke C, et al. (2012) The association between depression and leptin is mediated by adiposity. Psychosom Med 74: 39–43.
20. Adams HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, et al. (1993) Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 24: 35–41.
21. Timmins J, O’Connor MA, Schwartz RS, Guralnik JM, Sinaiko AR, et al. (2001) Portrait of a stroke survivor: results from a national survey. Stroke 32: 2067–2073.
22. Hatano S (1976) Experience from a multicentre stroke register: a preliminary report. Bull World Health Organ 54:311–318.
23. Adams HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, et al. (1993) Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 24: 35–41.
24. Edelstein D, Gershman E, Schaefer PW, Vangel M, Rosenthal ES (2009) ABC/2 for rapid clinical estimate of infarct, perfusion, and mismatch volumes. Neurology 72: 2104–2110.
26. Brott T, Adams HP Jr, Olinger CP, Marler JR, Barsan WG, et al. (1989) Measurements of acute cerebral infarction: A clinical examination scale. Stroke 20:864–870.

27. Bonita R BR (1988) Modification of Rankin Scale: recovery of motor function after stroke. Stroke 19:1497–1500.

28. Association AP (1987) DSM-III-R. Diagnostic and statistical manual of mental disorders. Washington, D.C: Amer Psychiatric Pub.

29. Jiménez I, Sobrino T, Rodríguez-Yáñez M, Pouso M, Cristobo I, et al. (2009) High serum levels of leptin are associated with post-stroke depression. Psychol Med 39:1201–1209.

30. Pasco JA, Jacka FN, Williams LJ, Henry MJ, Nicholson GC, et al. (2008) Leptin in depressed women: cross-sectional and longitudinal data from an epidemiologic study. Journal of Affective Disorders 107: 221–223.

31. Parkhami F, Tintut Y, Ballard A, Fogelman AM, Demer LL. (2001) Leptin enhances the calcification of vascular cells: artery wall as a target of leptin. Circ Res 88: 954–960.

32. Paolisso G, Tagliamoni MR, Galdersie M, Zito GA, D’Enrico A, et al. (2001) Plasma leptin concentration, insulin sensitivity, and 24-hour ambulatory blood pressure and left ventricular geometry. Am J Hypertens 14: 114–120.

33. Söderberg S, Olsson T, Eliasson M, Johnson O, Ahrén B. (1999) Plasma leptin levels are associated with abnormal fibrinolysis in men and postmenopausal women. J Intern Med 245: 533–543.

34. Zeman M, Jirak R, Jachymova M, Vecka M, Tvrzicka E, et al. (2009) Leptin, adiponectin, leptin to adiponectin ratio and insulin resistance in depressive women. Neuro Endocrinol Lett 30: 387–395.

35. Rubin RT, Rhodes ME, Czambel RK. (2002) Sexual dimorphism of baseline plasma leptin and leptin suppression by arginine vasopressin in major depressives and matched controls. Psychiatry Res 113: 255–268.

36. Ammara M, Kaloglu M, Tezcan E, Ustundag B. (2008) Serum leptin and cholesterol values in violent and non-violent suicide attempters. Psychiatry Res 156: 87–91.

37. Lawson EA, Miller KK, Blum JJ, Mcenasghen E, Misra M, et al. (2012) Leptin levels are associated with decreased depressive symptoms in women across the weight spectrum, independent of body fat. Clinical endocrinology 76: 520–525.

38. Deuschle M, Blum WF, Engelro P, Schweiger U, Weber B, et al. (1996) Plasma leptin in depressed patients and healthy controls. Horm Metab Res 28: 714–717.

39. Milaneschi Y, Sutin AR, Terracciano A, Canepa M, Graverstein KS, et al. (2014) The association between leptin and depressive symptoms is modulated by abdominal adiposity. Psychoneuroendocrinology 42:1–10.

40. Stanley LJ, Irving AJ, Harvey J. (2001) Leptin enhances NMDA receptor function and modulates hippocampal synaptic plasticity. J Neurosci 21: RC186.

41. Oda A, Taniguchi T, Yokoyama M. (2003) Leptin stimulates rat aortic smooth muscle cell proliferation and migration. Kobe J Med Sci 47: 141–150.

42. Boreet SG (2010) Neurodevelopmental actions of leptin. Brain Res 1350: 2–9.

43. Krishnan V, Nestler EJ (2010) Linking molecules to mood: new insight into the biology of depression. Am J Psychiatry 167: 1305–1320.

44. Chen K, Li F, Li J, Cai H, Strom S, et al. (2006) Induction of leptin resistance through direct interaction of C-reactive protein with leptin. Nature medicine 12: 425–432.

45. Penninx BW, Milaneschi Y, Lamers F, Vogelzangs N. (2013) Understanding the somatic consequences of depression: biological mechanisms and the role of depression symptom profile. BMC Med 11: 129.

46. Zupanic ML, Mahajan A. (2013) Leptin as a neuroactive agent. Psychosom Med 75: 407–414.

47. Söderberg S, Ahrén B, Stegmayr B, Johnson O, Wiklund PG, et al. (1999) Leptin is a risk marker for first-ever hemorrhagic stroke in a population-based cohort. Stroke 30: 328–337.